Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Unknown 5Recruiting 4Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 989Neoplasms 848Carcinoma, Non-Small-Cell Lung 842Prostatic Neoplasms 527Neoplasm Metastasis 500Leukemia, Myeloid, Acute 488Melanoma 453Colorectal Neoplasms 446Multiple Myeloma 440Lung Neoplasms 419Pancreatic Neoplasms 352Recurrence 350Lymphoma 349Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 327Leukemia 323Leukemia, Lymphocytic, Chronic, B-Cell 301Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 243Carcinoma, Hepatocellular 234Squamous Cell Carcinoma of Head and Neck 231Glioblastoma 231Myelodysplastic Syndromes 229Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

ricolinostat 1pomalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × Blood Protein Disorders × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡